Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1272
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 565–576 of 1,272 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337
Site status not listed — check the official record
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

NCT03055013
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
Interventions
Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
819 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
396
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Not yet recruiting Phase 2 Interventional

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

NCT07760948
Site status not listed — check the official record
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
Interventions
Calcium-HMB Plus Vitamin D3, Matching placebo
Dietary Supplement · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Active, not recruiting No phase listed Observational

X-linked Hypophosphatemia Disease Monitoring Program

NCT03651505
Site status not listed — check the official record
View directory record Official record
Conditions
X-linked Hypophosphatemia, Hypophosphatemic Rickets
Interventions
No intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Active, not recruiting Phase 3 Interventional

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The HOPE Biobank Resource (BMT CTN 2402 HOPE)

NCT07227155
Status at this site: Recruiting
View directory record Official record
Conditions
Aplastic Anemias, Hemoglobinopathies, Bone Marrow Failure
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
14
States / cities
Duarte, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Recruiting No phase listed Observational

An International Observational Study of Adults With Acute Infection

NCT07069400
Status at this site: Recruiting
View directory record Official record
Conditions
Infectious Disease
Interventions
No intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Recruiting Phase 2 Interventional

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

NCT05288790
Status at this site: Recruiting
View directory record Official record
Conditions
Microtia, Dysbiosis, Alcohol Drinking, HIV Infections, Cardiovascular Diseases
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Recruiting Phase 2 Interventional

Digoxin Medulloblastoma Study

NCT06701812
Status at this site: Recruiting
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
Interventions
Digoxin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
12 Months to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Recruiting No phase listed Observational

Physiological Brain Atlas Development

NCT00575081
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson's Disease, Obsessive Compulsive Disorder, Dystonia, Essential Tremor, Epilepsy
Interventions
Stereotactic brain procedures
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 90 Years
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Recruiting Phase 2 Interventional

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

NCT06533826
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
Interventions
Trastuzumab Deruxtecan, Datopotamab Deruxtecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 8:43 PM EDT
Not yet recruiting Phase 4 Interventional

Impact of Dysport on PMFF Donor Scar

NCT07720726
Site status not listed — check the official record
View directory record Official record
Conditions
Skin Cancer Excision Site, Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions
Abobotulinumtoxin-A, Control- Saline injection
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 8:43 PM EDT

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.